ThursdayAug 20, 2026 10:00 am

Former Adviser to Fauci Pleads Guilty to Covid-Related Conspiracy Charge

Dr. David Morens, formerly an adviser to Anthony Fauci during the Covid-19 pandemic, has pleaded guilty to a charge of conspiracy to conceal information about the pandemic. The charge focuses on attempts to conceal documents of the government by evading laws that allow members of the public to access records in the possession of the government.  The particulars of the charge brought against Morens in a Maryland federal court indicate that he undertook to conceal information about a research grant to a Chinese entity that had been identified as a possible origin of the pandemic.  Morens, aged 78, was indicted in April this year after prosecutors…

Continue Reading

WednesdayAug 19, 2026 10:30 am

Earth Science Tech Inc. (ETST) Continues Steady Growth with Acquisition of California-Based Compounding Pharmacy

Earth Science Tech, an expanding health-based holding company, recently announced the acquisition of Meduvo LLC, a compounding pharmacy that currently operates from a 2,000-square-foot facility in La Verne, California The acquisition grows the company’s network to 34 jurisdictions in the United States and establishes a strategic West Coast operational hub In addition to Meduvo, ETST also operates other compounding pharmacies through its specialized subsidiaries RxCompoundStore.com LLC (“RxCS”) and Mister Meds LLC Earth Science Tech (OTC: ETST), a strategic holding company in the healthcare, pharmacy, and telemedicine sector, recently acquired Meduvo LLC, a compounding pharmacy. Meduvo currently operates from a 2,000-square-foot…

Continue Reading

WednesdayAug 19, 2026 9:00 am

Quantum BioPharma Ltd. (NASDAQ: QNTM) Advances Myelin-Protecting MS Therapy as Treatment Paradigm Evolves

MS drug development is increasingly expanding beyond controlling inflammation toward approaches designed to protect the nervous system and address mechanisms underlying progressive disability. Remyelination and protection of existing myelin remain major unmet needs in MS, as no approved therapy has established the ability to restore previously damaged myelin. Quantum BioPharma’s Lucid-MS is a patented new chemical entity designed to inhibit demyelination and protect myelin without suppressing the immune system. The U.S. FDA has cleared Quantum BioPharma to proceed with its planned phase 2 clinical trial of Lucid-MS in people with multiple sclerosis. Multiple sclerosis (“MS”) treatment has traditionally focused on…

Continue Reading

TuesdayAug 18, 2026 10:00 am

Researchers Identify a Protein That Could Be Targeted in Glioblastoma Therapy

Glioblastoma is very difficult to treat because it quickly adapts and evolves to become resistant to existing treatments indicated for brain cancers. Now, scientists have found a protein on this cancer’s cells that could be targeted in order to make the cancer more vulnerable to the treatments administered to combat this deadly malignancy. The discovery was made by researchers based at the Comprehensive Cancer Center at Ohio State University. The findings of this preclinical study appeared in the journal Cancer Letters. The team wanted to find a way to make existing treatments like chemotherapy and radiotherapy more effective against this…

Continue Reading

FridayAug 14, 2026 10:30 am

Earth Science Tech Inc. (ETST) Seeks to Implement a Unified Strategy to Unlock True Market Value and Support Shareholders

Earth Science Tech seeks to implement a unified strategy aimed at maximizing shareholder value, resolving structural hurdles, and elevating corporate governance The company will hold a virtual annual meeting on August 31, 2026, during which shareholders will vote on key initiatives that will position ETST for an uplisting to a higher-tier exchange, eliminate the structural barriers that hinder the infusion of institutional capital, and prevent stock dilution These initiatives are informed by extensive dialogue between shareholders and management leading to a consensus that the company’s current market valuation simply does not accurately reflect its financial success or future potential The…

Continue Reading

FridayAug 14, 2026 10:00 am

Little-Known Immune Cells Bolster Anticancer Fight, Study Finds

Researchers from the University of Manchester in the UK have found that a small group of immune cells that aren’t given much attention by scientists is actually crucial in mobilizing the immune system to attack and sustain its fight against cancer.  The study, whose findings appeared in the journal Immunity, explored what impact the activation or deactivation of these particular immune cells would have on the body’s response to cancer.  For their study, the team designed mouse models in which it was possible to label or actually remove activated dendritic cells. Until this particular study was undertaken, it was hard for the research community to study the role of these cells during the…

Continue Reading

FridayAug 14, 2026 9:45 am

Regentis Biomaterials Ltd. (NYSE American: RGNT) Moves GelrinC Along Parallel US Clinical and European Commercial Tracks

Regentis has passed 50% enrollment in the pivotal Phase III SAGE study of GelrinC, with recruitment completion targeted for the third quarter of 2026 and a PMA process expected to begin by the end of 2027. FDA approved a single-arm protocol using a historical microfracture control data package the company owns, and Regentis reports that the first 40 patients closely match that control group. In Europe, where GelrinC already holds CE Mark approval, surgeon training began in the third quarter of 2026 at Humanitas Research Hospital in Milan, supported by an expanded clinical site network and a newly approved manufacturing…

Continue Reading

ThursdayAug 13, 2026 10:00 am

Global Drugmakers Earmark Billions to Ramp Up Their US Footprint

Dozens of global drugmakers are ramping up their investments in the United States in a bid to sidestep the planned tariffs on drug imports. In total, ongoing investments and planned expansions amount to approximately $500 billion.  These planned investments are intended to not only reassure investors but also mitigate risks linked to global supply chains, such as the evolving tariff environment.  Last September, Pfizer engaged in discussions with Trump, and the drugmaker undertook to invest about $70 billion in domestic R&D as well as manufacturing. In exchange, Trump granted the company an exemption of three years from any tariffs that are imposed on drug imports into…

Continue Reading

ThursdayAug 13, 2026 9:00 am

Regentis Biomaterials Ltd. (NYSE American: RGNT) Builds a Manufacturing and Intellectual Property Powerhouse for the Global Cartilage Repair Market

A new Japanese patent allowance follows a recent such US patent grant, strengthens protection around the organic solvent-free manufacturing process and ready-to-use liquid formulation behind GelrinC, extending the company’s intellectual property footprint into one of the world’s largest cartilage-repair markets. The process delivers a 5-fold increase in yield along with simplified production and commercial scalability, the manufacturing economics needed to make an off-the-shelf cartilage product commercially viable at scale. The milestone lands as Regentis advances European commercialization and passes the halfway mark in enrollment for its pivotal U.S. trial. Aging populations are pushing joint disease higher on the orthopedic agenda,…

Continue Reading

WednesdayAug 12, 2026 9:00 am

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Targets Disability Drivers Beyond Relapse Rates in Multiple Sclerosis

Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising. Researchers recognize that a large share of long-term disability accumulates independent of relapses altogether, a phenomenon researchers call progression independent of relapse activity. That shift has forced researchers to look at what is actually driving PIRA. A major suspect is chronic active lesions, sometimes called smoldering or mixed active-inactive lesions. Rather than broadly suppressing the immune system, Quantum BioPharma’s Lucid-MS is designed to inhibit myelin degradation, preserve myelin and support functional recovery. Multiple sclerosis is quietly shifting how drugmakers define success. Instead of judging a therapy mainly by…

Continue Reading

Official NewsWire Relationships

BIO Informa DGE Dynamic Global Events DTC Healthcare Conference Kiasco Reasearch Nexus Conferences Octane

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 512.354.7000